Drug Designing and Repositioning against Severe Acute Respiratory Coronavirus 2 (SARS-Cov-2) through Computational Simulation: Current Progress and Hopes

Authors: Waziha IT and Rashed N*

DOI: 10.23880/oajmb-16000168

Volume 5, Issue 3

Abstract

This is already well known that after the entry of the sever acute respiratory β-coronavirus-2 (SARS-CoV-2) into the host, the replication-associated proteins serve as the major targets of the currently used drugs. However, despite the rigorous effort, still no appropriate and specific drug against SARS-CoV-2 has been developed. Such a situation may worsen the current COVID-19 pandemic situation in near future. In this circumstance, the rapid drug application strategy can be addressed only by the drug repurposing approach which is solely based on the genomics functional analysis through computational simulation or the in silico study. Such a dry experimental strategy using the specialized databases and software allows identifying novel uses for the sanctioned drugs for other viruses. Based on the recently published reports, current review highlighted some promising drugs identified through such bioinformatic or molecular docking analysis.

Keywords: SARS-CoV-2; COVID-19 Pandemic; Drug Repurposing; Computational Simulation

View PDF